市場調査レポート

米国の脊椎手術用のオステオバイオロジック・骨成長刺激製品の市場

United States Markets for Osteobiologic and Bone Growth Stimulation Products for Spine Surgery

発行 Medtech Insight 商品コード 256503
出版日 ページ情報 英文 160 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
米国の脊椎手術用のオステオバイオロジック・骨成長刺激製品の市場 United States Markets for Osteobiologic and Bone Growth Stimulation Products for Spine Surgery
出版日: 2012年11月30日 ページ情報: 英文 160 Pages
概要

米国社会保健福祉省(HSS)によると、年間平均1340万人が腰痛のために病院を訪れ、また370万人が救急外来に搬送されています。痛みを取り除いて生活の質(QOL)を向上させるためには、脊椎固定が必要になる場合があります。米国の脊椎手術用のオステオバイオロジック・骨成長刺激製品の市場規模は、今後は年平均(CAGR)2.8%で成長し、2016年には21億1050万米ドルに達する、と予測されています。

当レポートでは、米国における脊椎手術用のためのオステオバイオロジック(osteobiologic)および骨成長刺激製品の市場について分析し、市場の特性・構造や競争状態、主な製品、部門別の市場動向見通しおよび製品開発・競争の状況、主要企業のプロファイルなどを調査・推計して、その結果を概略以下の構成でお届けします。

エグゼクティブ・サマリー

第1章 臨床概要

  • ヒトの脊椎
  • 骨の構造と機能
    • 骨の構造
    • 細胞の枠組み
    • 骨折の治癒過程
    • 骨の生理への影響要因
  • 代表的な脊椎障害
    • 椎間板ヘルニア
    • 変性椎間板疾患
    • 脊椎の異常湾曲
    • 脊椎すべり症
    • 狭窄症
    • 脊椎腫瘍
    • 外傷性脊椎損傷
    • 脊椎骨折
  • 脊椎治療のオプション
    • 脊椎減圧
    • 脊椎固定
      • 埋め込み型・非埋め込み型脊椎固定
      • 固定方法
    • 後部動的安定化装置
  • 市場のダイナミクス
    • 人口構成
    • 医療費還付
    • 医療制度改革法案(Patient Protection and Affordable Care Act)
    • 連邦政府による医師・企業間の関係性の監視
    • 手術件数の予測

第2章 脊椎手術に用いられる同種骨移植片製品

  • 同種移植片の供給業者に対する規制
  • 同種骨移植片の作成
    • 組織再生
    • 組織作成
  • 同種移植片の形態
    • 維持構造
    • 骨伝導用充填材
    • 骨伝導用素材
  • 同種移植組織の供給業者
  • 市場分析
    • 同種移植片の構造要素
    • 同種移植用充填材
    • 同種移植用骨基質
  • 競争分析

第3章 脊椎固定に用いられる合成骨移植片製品

  • 製品
  • 新規製品
  • 市場分析
  • 競争分析

第4章 脊椎固定に用いられる遺伝子組み換え骨形成タンパク質

  • 製品
    • インフューズ・ボーン・グラフト
    • 骨形成タンパク質-1
  • 新規製品
  • 市場分析

第5章 脊椎固定に用いられる電気的骨成長刺激装置

  • 直流式電気的骨成長刺激術
  • 静電結合式電気的骨成長刺激術
  • 複合的磁気式骨成長刺激術
  • パルス電磁場式骨成長刺激術
  • 医療費償還
  • 製品
  • 市場分析
  • 競争分析

第6章 企業プロファイル

  • AlloSource, Inc.
  • Biomet, Inc.
  • Integra LifeSciences Corporation
  • LifeNet Health, Inc.
  • Medtronic, Inc.
  • Musculoskeletal Transplant Foundation
  • Orthofix International NV
  • Stryker Corporation

付録:企業一覧

目次
Product Code: A336

Abstract

According to the United States (U.S.) Department of Health & Human Services, back pain accounts for approximately 13.4 million physician office visits and 3.7 million emergency room visits annually. Degeneration of an intervertebral disc that results in functionally limiting low back pain is a common condition that prompts patients to seek treatment. To eliminate or reduce pain and restore quality of life, patients with acute, debilitating pain may require spinal fusion.

During the forecast period covered by this report, the combined U.S. market for osteobiologic and bone growth stimulation products for spine surgery is projected to increase at a compound annual rate of 2.8%, reaching an estimated $2,110.5 million in the year 2016.

This dynamic new report from Medtech Insight includes analyses of the U.S. markets for allograft bone products, electrical osteogenic stimulators, recombinant human bone morphogenetic proteins, and synthetic bone grafts used in spine surgery. Also included in this report are company profiles of the leading competitors in these markets, as well as a clinical overview of the most common spinal diseases/disorders for which spinal fusion is indicated.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

Table of Contents

EXECUTIVE SUMMARY

  • i. Selected Spinal Disorders
    • a. Degenerative Disc Disease
    • b. Disc Herniation
    • c. Spinal Tumors
    • d. Traumatic Spinal Injuries
  • ii. Allograft Bone Products Used in Spine Surgery
    • a. Market Analysis
  • iii. Synthetic Bone Graft Products Used in Spinal Fusion
    • a. Market Analysis
  • iv. Recombinant Human Bone Morphogenetic Proteins Used in Spinal Fusion
    • a. Market Analysis
  • v. Electrical Osteogenic Stimulators Used in Spinal Fusion
    • a. Market Analysis
  • vi. Combined Market Forecast
  • vii. Methodology
  • Exhibit ES-1: Prevalence of Selected Spinal Disorders, 2011-2016
  • Exhibit ES-2: Incidence of Selected Spinal Disorders, 2011-2016
  • Exhibit ES-3: Allograft Bone Products Used in Spine Surgery, Market Forecast, 2011-2016
  • Exhibit ES-4: Synthetic Bone Graft Substitutes Used in Spinal Fusion, Market Forecast, 2011-2016
  • Exhibit ES-5: Recombinant Human Bone Morphogenetic Protein Products, Market Forecast, 2011-2016
  • Exhibit ES-6: Electrical Osteogenic Stimulators Used in Spinal Fusion, Market Forecast, 2011-2016
  • Exhibit ES-7: Osteobiologic and Bone Growth Stimulation Products for Spine Surgery, Combined Market Forecast, 2011-2016

1. CLINICAL OVERVIEW

  • 1.1 The Human Spine
  • 1.2 Bone Structure and Function
    • 1.2.1 Bone Formation
    • 1.2.2 Cellular Framework
      • 1.2.2.1 Osteoblasts
      • 1.2.2.2 Osteocytes
      • 1.2.2.3 Osteoclasts
    • 1.2.3 The Fracture Healing Process
    • 1.2.4 Factors Affecting Bone Physiology
      • 1.2.4.1 The Effect of Physical Stress on Bone Remodeling
      • 1.2.4.2 Age and Gender
      • 1.2.4.3 Physical Activity
      • 1.2.4.4 Obesity
      • 1.2.4.5 Cigarette Smoking, Alcohol, and Caffeine
      • 1.2.4.6 Nutritional Deficiencies
  • 1.3 Selected Spinal Disorders
    • 1.3.1 Disc Herniation
    • 1.3.2 Degenerative Disc Disease
      • 1.3.2.1 Arthritis
        • 1.3.2.1.1 Osteoarthritis
        • 1.3.2.1.2 Rheumatoid Arthritis
        • 1.3.2.1.3 Ankylosing Spondylitis
      • 1.3.2.2 Osteoporosis
      • 1.3.2.3 Spondylosis
    • 1.3.3 Abnormal Curvature of the Spine
      • 1.3.3.1 Scoliosis
      • 1.3.3.2 Kyphosis and Lordosis
    • 1.3.4 Spondylolisthesis
    • 1.3.5 Stenosis
    • 1.3.6 Spinal Tumors
    • 1.3.7 Traumatic Spinal Injuries
    • 1.3.8 Vertebral Fractures
  • 1.4 Spine Treatment Options
    • 1.4.1 Spinal Decompression
      • 1.4.1.1 Corpectomy
      • 1.4.1.2 Discectomy
      • 1.4.1.3 Facetectomy
      • 1.4.1.4 Foraminotomy/Foraminectomy
      • 1.4.1.5 Laminotomy/Laminectomy
    • 1.4.2 Spinal Fusion
      • 1.4.2.1 Instrumented versus Noninstrumented Spinal Fusion
        • 1.4.2.1.1 Instrumented Spinal Fusion
        • 1.4.2.1.2 Noninstrumented Spinal Fusion
      • 1.4.2.2 Types of Fusion
        • 1.4.2.2.1 Cervical Fusion
        • 1.4.2.2.2 Anterior Cervical Fusion
        • 1.4.2.2.3 Posterior Cervical Fusion
        • 1.4.2.2.4 Interbody Fusion
        • 1.4.2.2.5 Lumbar Fusion
          • 1.4.2.2.5.1 Anterior Lumbar Interbody Fusion
          • 1.4.2.2.5.2 Posterior Lumbar Interbody Fusion
          • 1.4.2.2.5.3 Transforaminal Lumbar Interbody Fusion
        • 1.4.2.2.6 Posterolateral Fusion
        • 1.4.2.2.7 360-Degree Fusion
        • 1.4.2.2.8 Thoracic and Thoracolumbar Fusion
        • 1.4.2.2.9 Percutaneous or Minimally Invasive Fusion
    • 1.4.3 Posterior Dynamic Stabilization
  • 1.5 Market Dynamics
    • 1.5.1 Demographics
    • 1.5.2 Reimbursement
    • 1.5.3 Patient Protection and Affordable Care Act
    • 1.5.4 Federal Oversight of Physician/Corporate Relationships
    • 1.5.5 Procedure Volumes Forecast
  • Exhibit 1-1: The Human Spine
  • Exhibit 1-2: The Structure of Collagen
  • Exhibit 1-3: The Structure of Hydroxyapatite
  • Exhibit 1-4: The Structure of Bone
  • Exhibit 1-5: Bone Density Averages in the General Population
  • Exhibit 1-6: Bone Density Averages in Olympic Athletes in Comparison with the General Population
  • Exhibit 1-7: Number of Overweight and Obese People, 2011 and 2016
  • Exhibit 1-8: A Herniated Disc
  • Exhibit 1-9: Bone Density in Normal and Osteoporotic Bone Tissue
  • Exhibit 1-10: Prevalence of Selected Spinal Disorders, 2011-2016
  • Exhibit 1-11: Incidence of Selected Spinal Disorders, 2011-2016
  • Exhibit 1-12: The Anatomy of a Spinal Segment
  • Exhibit 1-13: Noninstrumented Spinal Fusion
  • Exhibit 1-14: United States Population Growth Trends
  • Exhibit 1-15: Spinal Fusion Diagnosis-Related Groups and Associated Medicare Reimbursement
  • Exhibit 1-16: Spinal Fusion, Procedure Volumes Forecast, 2010-2016

2. ALLOGRAFT BONE PRODUCTS USED IN SPINE SURGERY

  • 2.1 Regulations Governing Allograft Providers
  • 2.2 Processing Allograft Bone
    • 2.2.1 Tissue Recovery
    • 2.2.2 Tissue Processing
  • 2.3 Allograft Forms
    • 2.3.1 Support Structures
    • 2.3.2 Osteoconductive Fillers
    • 2.3.3 Osteoinductive Materials
  • 2.4 Allograft Tissue Providers
  • 2.5 Market Analysis
    • 2.5.1 Allograft Structural Elements
    • 2.5.2 Allograft Fillers
    • 2.5.3 Demineralized Bone Matrix
  • 2.6 Competitive Analysis
  • Exhibit 2-1: 2012, Selected Allograft Bone Products Used in Spine Surgery
  • Exhibit 2-2: 2012, Selected Demineralized Bone Matrix Products
  • Exhibit 2-3: 2011, Comparison of Allograft Sales, by Distribution Channel
  • Exhibit 2-4: Allograft Bone Products Used in Spine Surgery, Market Forecast, 2011-2016
  • Exhibit 2-5: Allograft Bone Products Used in Spine Surgery, Market Segment Shares, 2011 and 2016
  • Exhibit 2-6: 2011, Market for Allograft Bone Products Used in Spine Surgery, Share by Supplier

3. SYNTHETIC BONE GRAFT PRODUCTS USED IN SPINAL FUSION

  • 3.1 Products
  • 3.2. Emerging Products
  • 3.3 Market Analysis
  • 3.4 Competitive Analysis
  • Exhibit 3-1: 2012, Selected Synthetic Bone Graft Products Used in Spinal Fusion
  • Exhibit 3-2: Synthetic Bone Graft Substitutes Used in Spinal Fusion, Market Forecast, 2011-2016
  • Exhibit 3-3: 2011, Market for Synthetic Bone Graft Substitutes Used in Spinal Fusion, Share by Supplier

4. RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEINS USED IN SPINAL FUSION

  • 4.1 Products
    • 4.1.1 Infuse Bone Graft
    • 4.1.2 Osteogenic Protein-1
  • 4.2 Emerging Products
  • 4.3 Market Analysis
  • Exhibit 4-1: Selected Bone Morphogenetic Proteins
  • Exhibit 4-2: 2012, Selected Recombinant Human Bone Morphogenetic Protein Products
  • Exhibit 4-3: Recombinant Human Bone Morphogenetic Protein Products, Market Forecast, 2011-2016

5. ELECTRICAL OSTEOGENIC STIMULATORS USED IN SPINAL FUSION

  • 5.1 Direct Current Electrical Osteogenic Stimulation
  • 5.2 Capacitive Coupling Electrical Osteogenic Stimulation
  • 5.3 Combined Magnetic Field Osteogenic Stimulation
  • 5.4 Pulsed Electromagnetic Field Osteogenic Stimulation
  • 5.5 Reimbursement
  • 5.6 Products
  • 5.7 Market Analysis
  • 5.8 Competitive Analysis
  • Exhibit 5-1: Direct Current Osteogenic Stimulators
  • Exhibit 5-2: Capacitive Coupling Osteogenic Stimulator
  • Exhibit 5-3: Combined Magnetic Field Osteogenic Stimulator
  • Exhibit 5-4: External Pulsed Electromagnetic Field Osteogenic Stimulators
  • Exhibit 5-5: Selected Indications for Electrical Osteogenic Stimulation Used in Spinal Fusion
  • Exhibit 5-6: 2012, Electrical Osteogenic Stimulator Products Used in Spinal Fusion
  • Exhibit 5-7: Electrical Osteogenic Stimulators Used in Spinal Fusion, Market Forecast, 2011-2016
  • Exhibit 5-8: 2011, Market for Electrical Osteogenic Stimulators Used in Spinal Fusion, Share by Supplier

6. COMPANY PROFILES

  • 6.1 AlloSource, Inc.
  • 6.2 Biomet, Inc.
  • 6.3 Integra LifeSciences Corporation
  • 6.4 LifeNet Health, Inc.
  • 6.5 Medtronic, Inc.
  • 6.6 Musculoskeletal Transplant Foundation
  • 6.7 Orthofix International NV
  • 6.8 Stryker Corporation

APPENDIX: COMPANY LISTING

Back to Top